Virological and Serological Characterization of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination.

Francesca Colavita, Silvia Meschi, Cesare Ernesto Maria Gruber, Martina Rueca, Francesco Vairo,
Giulia Matusali, Daniele Lapa, Emanuela Giombini, Gabriella De Carli, Martina Spaziante,
Francesco Messina, Giulia Bonfiglio, Fabrizio Carletti, Eleonora Lalle, Lavinia Fabeni, Giulia Berno,
Vincenzo Puro, Antonino Di Caro, Barbara Bartolini*, Giuseppe Ippolito, Maria Rosaria
Capobianchi, Concetta Castilletti, on behalf of INMI Covid-19 laboratory surveillance team

8

- 9 Affiliation: National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy
- 10
- 11 * Corresponding author:
- 12 Barbara Bartolini, PhD
- 13 Laboratory of Microbiology and Biorepository
- 14 National Institute for Infectious Diseases "L. Spallanzani"
- 15 Via Portuense 292, 00149 Rome, Italy
- 16 Tel: +39 0655170685; Fax +39 065594555
- 17 e-mail: barbara.bartolini@inmi.it

18

- 19
- 20
- 21
- 22
 - NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 Abstract

25 Coronavirus disease 2019 (COVID-19) vaccines are proving to be very effective in preventing 26 severe illness; however, although rare, post-vaccine infections have been reported. The present 27 study describes 94 infections (47.9% symptomatic, 52.1% asymptomatic), occurred in Lazio Region (Central Italy) in the first trimester 2021, after first or second dose of mRNA BNT162b2 28 29 vaccine. Median viral load at diagnosis was independent from number and time of vaccine dose administration, despite the higher proportion of samples with low viral load observed in fully 30 31 vaccinated individuals. More importantly, infectious virus was cultured from NPS collected from both asymptomatic and symptomatic vaccinated individuals, suggesting that, at least in principle, 32 they can transmit the infection to susceptible people. The majority of the post-vaccine infections 33 here reported, showed pauci/asymptomatic clinical course, confirming the impact of vaccination on 34 35 COVID-19 disease. Most cases (78%) showed infection in presence of neutralizing antibodies at the time of infection diagnosis, presumably attributable to vaccination, due to the concomitant 36 absence of anti-N IgG in most cases. The proportion of post-vaccine infections attributed either to 37 Alpha and Gamma VOCs was similar to the proportion observed in the contemporary unvaccinated 38 population in Lazio region. In addition, mutational analysis did not suggest enrichment of a defined 39 set of Spike protein substitutions depending on the vaccination status. Characterization of host and 40 virus factors associated with vaccine breakthrough, coupled with intensive and continuous 41 42 monitoring of involved viral strains, is crucial to adopt informed vaccination strategies.

44 Introduction

In less than 12 months after the beginning of the COVID-19 pandemic, scientific research 45 46 succeeded in developing multiple vaccines against a previously unknown viral pathogen, severe 47 acute respiratory coronavirus 2 (SARS-CoV-2). The mRNA-based Pfizer-BioNTech vaccine (BNT162b2) has been the first authorized, and on 27 December 2020, the European Union 48 countries launched a co-ordinated vaccination campaign that initially was prioritized for individuals 49 at high risk of SARS-CoV-2 exposure, such as the health-care workers (HCW), and for those at 50 51 high risk of severe COVID-19, including elderly and residents of assisted living facilities. One key point is to identify and follow up post-vaccine infections and to assess vaccine effectiveness in 52 reducing disease severity and limiting infection transmission to unvaccinated individuals. As 53 expected due to the fact that COVID-19 vaccines do not offer 100% protection against the SARS-54 55 CoV-2 infection, current evidence showed that individuals who received full vaccination can become infected ¹; however, they seem to have lower risk to develop severe COVID-19 compared 56 57 to unvaccinated people, and to carry reduced viral loads with a likely lower transmission to others ²⁻⁵. Nevertheless, definitive evidences are still lacking. An additional concern for vaccine 58 effectiveness is about SARS-CoV-2 variants in the Spike protein, which are emerging and 59 spreading across the globe; in fact, some showed potential of immunological escape from the 60 antibodies response that could impact the vaccination efficacy and lead to COVID-19 epidemic 61 rebounds ⁶⁻⁸. A specific surveillance on SARS-CoV-2 variants has been established in Lazio 62 63 Region (Central Italy) in line with the national and international guidelines ¹. SARS-CoV-2 positivity after vaccination is one of the priority recommendation for genomic characterization in order to 64 identify genetic changes that may be associated with vaccine escape. Here, we described 65 virological and serological testing performed at the Regional Reference Laboratory (RRL) of 66 67 Virology of the National Institute for Infectious Diseases "L. Spallanzani" (INMI) in Rome, Italy, on samples collected at the time of first RT-PCR positivity from 94 individuals, who resulted positive 68 for SARS-CoV-2 between December 27 and March 30, 2021, following one or two doses of 69 BNT162b2 vaccine. 70

71 Materials and Methods

72 Study group

In the frame of the Regional Surveillance programme, naso-pharyngeal swabs (NPS) and, 73 74 possibly, sera collected from individuals who resulted positive for SARS-CoV-2 after vaccination were sent to INMI in Rome, Italy, for further laboratory investigation. These individuals were tested 75 at peripheral laboratories either following symptoms onset, for contact tracing or screening 76 activities. In this study, we included the first batch of samples (94 NPS) which were referred 77 78 between December 27 and March 30, 2021 to the RRL at INMI for virological evaluation of postvaccination RT-PCR positivity occurred at least one day after one or two BNT162b2 vaccine doses 79 and for which in-depth analysis was completed. For 79 individuals, a known date of vaccination 80 was reported and the time lapsing from vaccination to sample collection was calculated. We 81 82 classified the individuals with known vaccination date into three groups based on the time elapsed from the first dose of vaccine to infection, i.e. time of SARS-CoV-2 positive test or symptoms onset 83 (here considered both as infection starting date): Group 1, individuals tested positive 1 to 15 days 84 after first dose; Group 2, 16 to 30 days after first dose vaccination, and Group 3, >30 days from 85 86 first dose, 10 days after the second dose injection (considered as full vaccinated group). For 50 individuals (44 of them with reported date of vaccination), a serum sample collected at time of 87 diagnosis was also available for serological testing. In fact, according to the local surveillance 88 system, serum collection was recommended but not mandatory for post-vaccine infections follow-89 90 up. NPS and serum samples were shipped to INMI under controlled temperature (-80°C and refrigerated at +4°C, respectively). 91

Sequencing data (n=1072) produced at INMI exclusively from randomly selected samples collected
from unvaccinated individuals during the same study period and representing all the regional
territory, were used to evaluate the prevalence of variants of concern (VOCs).

95 Molecular testing and virus characterization

Semi-quantitative estimation of viral load was assessed by RT-PCR using DiaSorin Simplexa®
 COVID-19 Direct platform (DiaSorin, Saluggia, Italy), based on cycle threshold (Ct) value. For
 whole-genome sequencing, nucleic acid extraction was performed using QiaSymphony automatic

extractor and the DPS Virus/Pathogen Midi Kit (QIAGEN), followed by Next-Generation 99 Sequencing (NGS) carried out on Ion Torrent or Illumina Platform using Ion AmpliSeg SARS-CoV-100 2 Research Panel, following manufacturer's instructions (ThermoFisher, US). Sequencing was 101 performed on Ion Gene Studio S5 Sequencer and on Illumina MiSeq. Complete genome 102 sequences were obtained combining in-house pipeline ESCA⁹ with IRMA¹⁰ and DRAGEN RNA 103 Pathogen Detection 3.5.15 (Illumina BaseSpace) software, and submitted on GISAID platform ¹¹. 104 105 In case of low coverage for the full-genome characterization, Sanger sequencing was used to fill 106 the NGS gaps in the Spike coding gene.

107 Virus isolation

Viral culture was performed in a biosafety level 3 (BSL-3) laboratory at INMI on Vero E6/TMPRSS2
 (kindly provided by Dr. Oeda S., National Institute of Infectious Diseases, Tokyo, Japan), as
 previously described ¹².

111 Serological testing

Serological investigation included the detection of anti-N and anti-RBD Spike IgG using Abbott 112 SARS-CoV-2 assay on Abbott ARCHITECT® i2000sr (Abbott Diagnostics, Chicago, IL, USA) and 113 the evaluation of the neutralising antibodies (nAb) titres using SARS-CoV-2 microneutralization test 114 (MNT) based on live virus ¹³. The viral strain used in MNT (lineage B.1 - clade G; GISAID 115 accession number: EPI ISL 568579; EVAG Ref-SKU: 008V-04005) had been isolated in March 116 2020 in Italy and kindly provided by Prof. Baldanti F, Fondazione IRCCS Policlinico San Matteo, 117 Pavia, Italy. SARS-CoV-2 neutralization titers are expressed as the reciprocal of serum dilution 118 achieving 90% reduction of cytopathic effect. First international standard for anti-SARS-CoV-2 119 provided by the National Institute for Biological Standards and Control (NIBSC, UK) was used as 120 121 reference in MNT (Research reagent for anti-SARS-CoV-2 human immunoglobulin, NIBSC code: 122 20/136).

123 Statistics

Epidemiological and demographic data were extracted from the Regional Surveillance Information System established by the regional health authority and analyzed using the STATA 14 software. Demographic characteristics of the vaccinated individuals were described using median and

interquartile range (IQR) for continuous parameters, and absolute and relative (percentage) frequencies for categorical variables. Inferential analysis of association were performed using chisquare or Fisher exact tests for categorical variables, and Mann–Whitney or Kruskal-Wallis tests for continuous parameters. Univariate analysis using Odd Ratio (OR) with 95% interval of confidence (95%CI) are shown. Analyses were performed using GraphPad Prism version 8.00 (GraphPad Software, La Jolla California) and SPSS V.23 for Windows statistical software; pvalue<0.05 was considered statistically significant.</p>

134 Ethics

This work was performed within the framework of the COVID-19 outbreak response and surveillance program and the laboratory characterization of post-vaccination infections by INMI laboratory as the RRL, is essential part of the Lazio surveillance regional plan. Use of laboratory and epidemiological records for research purpose has been approved by the INMI Ethical Committee (issue n. 214/20-11-2020), and the need of informed consent form was waived. The study has been conducted in respect of current legislation on personal data protection, all data are presented in non-identifiable form.

142 **Data availability statement**

Sequencing data that support the findings of this study have been deposited in GISAID; the list of the accession codes is available from the corresponding author on reasonable request. The other data used and/or analyzed during the current study are available, only for sections non-infringing personal information, from the corresponding author upon request.

147 Results

148 Cases of SARS-CoV-2 infections after BNT162b2 vaccination

According to the Regional Surveillance Information System of the Lazio regional health authority, from the 27th of December 2020, the start of the vaccination campaign, up to 30th March 2021, 735,616 individuals received one or two doses of BNT162b2 vaccine. Among these, 1,879 (0.3%) tested positive for SARS-CoV-2 positive at least 1 day after vaccination. The majority (79.5%) of these individuals are reported positive before the second dose injection.

In the study period, samples from 121 out of the reported 1,879 infections in vaccinated persons 154 were recovered from the laboratories that performed the diagnosis, and sent to the RRL to perform 155 the characterization foreseen in the framework of the COVID-19 outbreak response and 156 157 surveillance program established in Lazio Region. The results described in this study represent those obtained on the first 94 NPS for which analysis was completed. The median time between 158 infection recognition (as symptoms onset or time of first diagnosis for asymptomatic patients) and 159 testing was 0.5 days (range: 0-9 days, with 7 tested samples collected >4 days after diagnosis or 160 161 symptoms onset).

Demographic and epidemiologic data, including clinical information, are shown in Table 1. The 162 majority (n=82, 87.2%) of the 94 individuals under investigation was HCW, the remaining samples 163 were from elderly people (over 80 years old). Median age was 50.5 years old (IQR: 62.0-39.8), 56 164 (59.6%) were female. Forty-nine (52.1%) were asymptomatic at the diagnosis, and underwent 165 SARS-CoV-2 testing for periodic screening or as contacts of positive cases. The majority (n=61, 166 167 64.9%) of post-vaccination cases had a pauci/a-symptomatic clinical course, while a mild disease was reported for 26 (27.7%), and severe for 7 (7.4%) patients. All patients with severe disease had 168 169 one or more pre-existing co-morbidities, including cardiovascular chronic diseases, diabetes, obesity, renal affections, and neurological disorders, 4 were over 80 years old. Age and co-170 morbidities were significantly associated with severe disease (p=0.008 and <0.001, respectively). 171 According to the information available at the time of writing (n=85), most infected persons (97.6%) 172 173 cleared the virus and recovered, while 2 patients died; both dead patients were over 85 years old, presented pre-existing co-morbidities (i.e., cardiovascular chronic diseases, diabetes and 174 neurological disorders), and tested positive after full vaccination (9 and 19 days after the second 175 dose, respectively). 176

For 79 individuals, a known date of vaccination was reported **(Table 1)**. The median time between the first-dose vaccination and symptoms onset, or time of first diagnosis for asymptomatic cases, was 47 days, ranging from 1 to 85 days after the first dose (corresponding to 64 days following the full vaccination). Fifty-four (68.4%) individuals resulted infected after full vaccination.

181 Symptoms at diagnosis and hospitalization rate were significantly more frequent in patients 182 infected after a single dose as compared to patients infected after full vaccination course; a trend 183 towards less frequent severe course was observed in infections acquired after two doses.

184 SARS-CoV-2 viral loads and infectivity in NPS from individuals infected up to 2 months after

185 full vaccination

Median Ct values of NPS at diagnosis was 21.2 (IQR: 17.5-31.3), with no significant difference 186 between asymptomatic and symptomatic presentation (median Ct values: 22.0 vs 19.6, Figure 187 188 1A), even in those patients tested positive after full vaccine course (median Ct values: 21.8 vs 18.9; Figure 1A). To understand whether viral RNA was associated to infectiousness, virus 189 isolation was attempted on 84 NPS; 10 NPS were not tested due to due to viral infectivity 190 191 inactivation by guanidine isothiocyanate contained in the transport medium used for sample 192 collection. Notably, infectious virus was rescued from 44 (52.4%) NPS, 24 collected from 193 symptomatic individuals, 20 collected from asymptomatic subjects. No significant difference in 194 culture positivity rates were found between these two groups (54.5% in symptomatic vs 50.0% in asymptomatic, p=0.827). Similar results were obtained when considering fully vaccinated patients 195 only (60.9% in symptomatic vs 48.2% in asymptomatic, p=0.567). The proportion of samples with 196 low viral load (Ct values >30) in asymptomatic individuals (32.6%) was higher compared to the 197 symptomatic patients (20.0%), but did not reach statistical significance (p=0.242). 198

We next considered the viral RNA levels according to time lapsed from first dose to diagnosis, 199 200 known for 79 individuals, who were divided in 3 groups. The results indicated similar median Ct values in all 3 groups (Fig. 1B), despite the higher proportion of samples with low viral load in 201 202 Group 3. This finding coupled with the isolation rate, which was found higher in samples collected 203 shortly after the vaccination (Group 1), but did not reach statistical difference compared to the 204 other groups (Group 1: 85.7%, Group 2: 40.0%; Group 3: 54.0%, p=0.411). As shown in detail in Figure 2, over 39 positive viral cultures, 27 (67.5%) were obtained from fully vaccinated 205 206 individuals, who tested positive for SARS-CoV-2 up to 85 days after the first vaccination dose. The 207 median Ct value of the samples with positive viral culture was 17.5 (IQR 15.6-20.1), and isolation

of infectious virus was strongly associated only with the viral RNA concentration in the NPS, with
 OR >100 for Ct≤25 vs Ct>25 (Table 2).

210 Antibody response at the time of infection diagnosis

Serological testing was performed on the available serum samples (n=50) which have been 211 collected at the time of diagnosis at the peripheral laboratories and sent to the RRL 212 (Supplementary Table 1). The results showed that antibody response was detected in 48 213 individuals (96.0%, median anti-RBD Spike IgG BAU/ml=704.6, IQR 403.0-2111.0) at the time of 214 infection diagnosis since first dose vaccination; 42 (84.0%) of them presented also detectable nAb 215 (median titre=1:80, IQR 1:40-1:160), mostly (66.7%) fully vaccinated. Eight vaccinees (16.0%) did 216 not show detectable nAb at diagnosis, of whom 2 (4.0%) were fully vaccinated (both over 80 years 217 218 old and presenting co-morbidities), indicating primary non response to vaccine. Out of 44 samples 219 collected from individuals with known date of vaccination, we observed significant differences in antibody titres, both anti-RBD Spike IgG and nAb (Figure 3A-B), along the different time-points 220 221 from vaccination, with high titres after 15 days from the first dose (Groups 2 and 3). Unexpectedly, Group 2 presented higher antibody levels compared to Group 3, which included fully vaccinated 222 223 individuals. This difference resulted statistically significant for anti-S IgG (p<0.01), not for 224 neutralizing antibodies.

225 Since anti-N IgG seroconversion at diagnosis was observed only in 3 patients (6.0%), we 226 reasonably argue that the detected functional antibody response was mostly (39/50, 78.0%) elicited by vaccination, and not by the infection per-se. In addition, we have formal evidence of pre-227 infection (38 and 60 days before infection) vaccine-induced antibodies response in two patients, 228 with nAb titers of 1:160 at day 15 from full immunization for both infections. As shown in Figure 3B 229 and **Supplementary Table 1**, the presence of nAb in serum did not preclude virus isolation from 230 231 NPS, and titres were not correlated with viral load (median Ct values: 21.5, IQR 16.5-32.2; Spearman r=0.220, p-value=0.124). Notably, data from Table 2 show a trend to negative 232 association of viral isolation rate with high nAb titers (OR=0.28 for nAb ≥1:80 vs <1:80). 233 Considering the immune status in relation to the clinical course of post-vaccination infections, no 234 235 statistically significant differences in both anti-RBD Spike IgG and nAb median values were found

amongst the different groups of disease severity **(Supplementary Figure 1)**, with no significant association between clinical course and presence or high titres (\geq 1:80) of nAb (p=0.082 and 0.224, respectively).

239 Distribution of VOCs in post-vaccination infections

We next investigated the viral variants infecting the vaccinated individuals included in this study. 240 Whole-genome sequences (WGS) were obtained from the 58 NPS samples with adequately high 241 242 viral load (Ct<28); additional variant strain identification was obtained for 6 patients by partial 243 Sanger sequencing of the S region. Out of these 63 SARS-CoV-2 sequences, 15 (23.8%) belonged to B.1.177 lineage (GV clade), 14 (22.2%) were Gamma variants (P.1 lineage, GR clade) 244 and 28 (44.4 %) were Alpha variants (B.1.1.7 lineage, GRY clade). One (1.6%) resulted to be 245 Variant of Interest (VOI) Eta (B.1.525 lineage, G clade), and 5 (7.9%) sequences belonged to other 246 clades with 3 sequences to the clade GR (i.e., 2 of the B.1.1 lineage, 1 of the B.1.1.39 lineage) and 247 2 to the clade G (i.e., 1 of the B.1 lineage and 1 of the B.1.258.17 lineage) (Supplementary 248 249 Figure 2A). The distribution of variants amongst the vaccinated individuals grouped according to 250 vaccination status (i.e., days from vaccination) was related to the time of infection diagnosis and 251 reflected mostly the circulation of the variants in the general population at the time of the infection (Supplementary Figure 2B). For instance, B.1.1.7 was detected mainly in those vaccinated 252 individuals who tested positive in March 2021, regardless the vaccination status; accordingly, 253 254 Group 3 showed the predominance of B.1.1.7 as this group included mainly vaccinated individuals 255 who tested positive in March 2021. As matter of fact, when we compared our study population to 256 unvaccinated contemporary population, based on 1072 samples randomly collected from Lazio patients between January and March 2021 and sequenced by NGS and Sanger for surveillance 257 purpose, we observed that variants prevalence in vaccinated individuals followed the circulation in 258 259 the general population. In fact, as shown in Figure 4, we observed a similar temporal distribution between the two groups, with a clear increase of B.1.1.7 followed by P.1 in both groups, without 260 significant difference for both P.1 (p=0.08 in Chi-square test) and B.1.1.7 lineages (p=0.20 in Chi-261 square test) (Figure 4). Mutational analysis of Spike protein sequences obtained by NGS showed 262 263 that signature mutations for the VOCs are observed in all groups, and other changes are found in a

264 minority of patients **(Supplementary Figure 3)**; especially for P.1, none of these minor changes 265 seems to be enriched in Group 3, suggesting no association with more resistant forms.

The rate of infectious virus isolation in the vaccinated patients was similar when dividing the vaccinated patients according to the infecting virus variants (culture positivity rate: B.1.177; 80.0%; P.1: 71.4%; B.1.1.7, 72.7%; others, 66.7%), with no significant differences in median Ct values amongst the variants (p=0.109) **(Supplementary Figure 4)**. Notably, these findings need to be carefully interpreted since only NSP with high viral loads have been sequenced in order to have an adequate coverage for the full-genome characterization and this could actually bias the analysis.

272 Discussion

The present study analyses 94 infections, occurring in Lazio Region (Central Italy) after first or second dose administration of mRNA BNT162b2 vaccine, both from the host side (patients' demographics, infection severity, antibody status) and from the virus side (viral load, infectivity and infecting variants).

277 Encouraging evidence is accumulating worldwide about vaccine effectiveness against COVID-19 in real-life vaccination campaigns¹⁴. Several case-control and population-level studies reported that 278 vaccination substantially reduce both asymptomatic and symptomatic infections, with more 279 significant impact after at least 7 days from the second dose ^{2,15–18}. SARS-CoV-2 infections in 280 previously vaccinated individuals are sporadic events compared to the total number of vaccine 281 administrations. Several recent studies including trials and observational reports, showed a lower 282 283 risk of documented cases in household members of vaccinated HCW and reduced viral load in newly-infected individuals with previous vaccination ^{2,5,19}. This has been translated in hypothetical 284 lower infectivity and transmission risk. However, scientific evidence of COVID-19 vaccine 285 effectiveness against infectiousness of SARS-CoV-2 is still limited. 286

Our data show that vaccinated individuals who get infected after vaccination, although representing a tiny proportion of the vaccinated population (0.3% in our setting), may carry high viral loads in the upper respiratory tract, even when infected long time after the second dose, i.e. when vaccinerelated immunity should have been developed. More importantly, we evidenced for the first time

291 that infectious virus can be cultured from NPS collected from both asymptomatic and symptomatic vaccinated individuals, suggesting that they could be able to transmit the infection to susceptible 292 293 people and potentially be part of transmission chains. As observed for infections in unvaccinated people, high viral load (Ct≤25) is a strong determinant of isolation success ^{20,21}. This finding should 294 be carefully considered for public health policy, emphasizing the importance of a proper 295 296 communication that vaccine does not confer sterilizing immunity; therefore, continued adherence to 297 public health prevention measures is still recommended for vaccinated individuals until adequate 298 vaccination coverage of the population is reached or in presence of susceptible vulnerable individuals ^{5,22,23}. On the other hand, the very small proportion of post-vaccine infections is 299 encouraging that overall risk of transmission from vaccinated persons will be low, supporting the 300 301 crucial role of vaccination.

The impact of emerging variants on the vaccination campaigns is under investigation as vaccine 302 escape variants may be associated to increased vaccine failure ⁶. In the vaccinated individuals 303 described in this study, the majority of infections were caused by Alpha VOC (B.1.1.7), followed by 304 the previously predominant strain in Lazio Region, B.1.177, and by the Gamma VOC (P.1). As 305 recently reported in the United States ²², the temporal distribution of the variants identified in the 306 vaccinated individuals clearly matches the pattern of strains circulation in the unvaccinated 307 population of the Lazio Region, with no evidence of vaccine-related immune escape. The 308 309 preliminary analysis of a more recently collected set of data confirms similar patterns of VOC 310 distribution (both B.1.1.7 and P.1) in vaccinated and unvaccinated individuals from Lazio region, at 311 least up to May 2021, i.e. before the ramp up of the new Delta variant (data not shown).

In a recent study from Israel, Kustin et al. ²⁴ reported that infection with Beta VOC was disproportionally detected in fully vaccinated individuals, while Alpha VOC was disproportionally involved in infections diagnosed between 2 weeks after the first dose and 6 days after the second dose. The differences with our results may be due to different pattern of VOCs circulation, as, for example, circulation of Beta VOC was very tiny in our territory. In addition, Spike mutations in each lineage, broken down by Groups 1, 2 and 3, indicated that there is no selection for enrichment of

any particular mutation in fully vaccinated individuals (Group 3) as compared to individuals withincomplete vaccination (Groups 1 and 2).

Serological findings showed that the majority (84.0%) of the individuals who tested positive after 320 321 vaccination had nAb at the time of diagnosis; 64.3% of them, infected after second dose administration, showing relevant nAb titres (≥1:80). Although antibody immune status following 322 vaccination and prior infection was not available for most of these individuals (except for two 323 324 cases, who underwent serological testing before the infection), in line with recent report ²⁵, the nAb 325 titers measured shortly after the infection, together with negative anti-N IgG serology, suggest that it is very likely that they had a immune responses to the vaccine, yet not sufficient to prevent the 326 327 contagion. On the contrary, 8 individuals tested SARS-CoV-2-positive after vaccination did not present nAb, 2 of them reported as fully vaccinated, suggesting primary non response to vaccine. 328 Unexpectedly, Group 2 presented the highest antibody levels, even compared to Group 3 which 329 included fully vaccinated individuals; while it is reasonable that antibody levels in Group 2 is higher 330 than in Group 1 (due to the longer interval from vaccine administration), the observed difference 331 between Group 2 and 3 seems not to be explained with the available information concerning 332 333 symptomatic versus asymptomatic infection and distance from symptoms onset, which resulted to 334 be similar between the two groups. A weak response to the vaccination may be a possible explanation. Studies including larger population will help clarify this point. In addition, our data 335 showed that the presence of nAb in serum did not preclude isolation of replication-competent virus 336 337 from NPS of vaccines; however, the relationship between the infectivity of released virus and the 338 presence of nAb in serum or in the nasopharyngeal tract deserves to be better investigated through dedicated studies. 339

According to previous reports, the majority of infections observed in vaccinated individuals in this study had a mild or asymptomatic clinical course, and those patients with severe symptoms presented pre-existing co-morbidities and lower median antibody levels compared to those who had a mild or asymptomatic presentation. Two deaths were observed, both in patients over 85 years old and with multiple co-morbidities, which represent a relevant risk factors for severe disease and are prognostic for negative outcome ^{4,26–28}. This confirms overall vaccine effectiveness

against the disease, which represents a key factor to control morbidity and mortality of SARS-CoV2 infection, as well as to reduce the public health burden of this pandemic together with social and
economic global crisis.

349 Our study presents some limitation that should be acknowledged. First, the study was an observational study based on real-life data obtained from pandemic surveillance activities, aimed 350 not to establish vaccine efficacy compared to a matched unvaccinated control group, but, to report 351 a virological characterization of those patients reported with SARS-CoV-2 infection despite being 352 353 vaccinated. Therefore, our observation should be replicated and extended on larger cohorts 354 established ad hoc and to other vaccine formulations. Furthermore, no follow-up samples were available for the post-vaccination infected individuals, so that it was not possible to monitor the viral 355 356 loads and the shedding of infectious virus. In addition, as described above, pre-infection antibody status was only available for few patients. Finally, the evaluation of the cellular immune response 357 would be of great interest to better understand the protection status in cases of vaccine 358 breakthrough infections. 359

360

361 Acknowledgement

We gratefully acknowledge the Local Health Authorities and the laboratory network (CoroNET) of the Lazio Region. We acknowledge also the contributors of genome sequences of the newly emerging coronavirus (i.e., the originating and submitting laboratories) for sharing their sequences and other metadata through the GISAID Initiative.

INMI Covid-19 laboratory surveillance team: Abbate Isabella, Agrati Chiara, Agresta 366 Alessandro, Aleo Loredana, Alonzi Tonino, Amendola Alessandra, Apollonio Claudia, Arduini 367 Nicolina, Bartolini Barbara, Berno Giulia, Bettini Aurora, Biancone Silvia, Biava Mirella, Bibbò 368 369 Angela, Bonfiglio Giulia, Bordi Licia, Brega Carla, Butera Ornella, Canali Marco, Cannas Angela, Capobianchi Maria Rosaria, Carletti Fabrizio, Carrara Stefania, Casetti Rita, Castilletti Concetta, 370 Chiappini Roberta, Ciafrone Lucia, Cimini Eleonora, Coen Sabrina, Colavita Francesca, Condello 371 Rossella, Coppola Antonio, D'Alessandro Gaetano, D'Arezzo Silvia, D'Amato Maurizio, De Santi 372 373 Claudia, Di Caro Antonino, Di Filippo Stefania, De Giuli Chiara, Fabeni Lavinia, Federici Luigi,

Felici Luisa, Ferraioli Valeria, Forbici Federica, Francalancia Massimo, Fusco Maria Concetta, 374 Garbuglia Anna Rosa, Giombini Emanuela, Gramigna Giulia, Graziano Silvia, Gruber Cesare 375 Ernesto Maria, lazzetti Roberto, Khouri Daniele, Lalle Eleonora, Lapa Daniele, Leone Barbara, 376 377 Leone Sara, Marafini Giovanni, Marchetti Federica, Massimino Chiara, Matusali Giulia, Mazzarelli Antonio, Meschi Silvia, Messina Francesco, Minosse Claudia, Montaldo Claudia, Mucciante Mirco, 378 Nazzaro Clara, Neri Stefania, Nisii Carla, Petrivelli Elisabetta, Petroni Fabrizio, Petruccioli Elisa, 379 380 Pisciotta Marina, Pitti Giovanni, Pizzi Daniele, Prota Gianluca, Rozera Gabriella, Rueca Martina, 381 Sabatini Rossella, Santini Francesco, Sarti Silvia, Sberna Giuseppe, Sciamanna Roberta, Scionti Rachele, Selleri Marina, Specchiarello Eliana, Stellitano Chiara, Toffoletti Antonietta, Tonziello 382 Gilda, Truffa Silvia, Turchi Federica, Valli Maria Beatrice, Vantaggio Valentina, Venditti Carolina, 383 Vescovo Tiziana, Vincenti Donatella, Vulcano Antonella, Zambelli Emma. 384

385 **Contributions**

Study design: C.C., F.C., S.M., B.B., M.R.C., A.D.C.; Laboratory investigation: F.C., S.M., M.R.,
G.Bo., G.M., D.L., F.C., E.L., L.F., G.Be.; Data collection: F.C., M.R., E.L., G.Be, G.Bo., F.V., M.S.,
G.D.C., V.P.; Data analysis: F.C., F.V., C.G., E.G., F.M., L.F.; Data interpretation: F.C., C.G., C.C.,
F.V., M.R.C., A.D.C., Writing: F.C. and M.R.C., with revisions and comments from all authors;
Funding acquisition: C.C., A.D.C., M.R.C., G.I.. INMI COVID-19 laboratory surveillance Team
contributed to the data and samples collection and storage, and routine diagnostic and
epidemiological analyses.

393 Funding

The study was performed in the framework of the SARS-CoV-2 surveillance and response program implemented by the Lazio Region Health Authority. This study was supported by funds to the Istituto Nazionale per le Malattie Infettive (INMI) Lazzaro Spallanzani IRCCS, Rome (Italy), from Ministero della Salute (Programma CCM 2020; Ricerca Corrente - linea 1; COVID-2020-12371817); the European Commission – Horizon 2020 (EU project 101003544 – CoNVat; EU project 101005111-DECISION; EU project 101005075-KRONO) and the European Virus Archive – GLOBAL (grants no. 653316 and no. 871029).

401 Authors Disclosure

402 The authors declare no conflicts of interest.

403 References

- 1. European Centre for Disease Prevention and Control. Risk of SARS-CoV-2 transmission
- 405 from newly-infected individuals with documented previous infection or vaccination. 29th
- 406 *March* (2021). Available at: https://www.ecdc.europa.eu/en/publications-data/sars-cov-2-
- 407 transmission-newly-infected-individuals-previous-infection. (Accessed: 6th May 2021)
- 408 2. Levine-Tiefenbrun, M. et al. Initial report of decreased SARS-CoV-2 viral load after
- 409 inoculation with the BNT162b2 vaccine. *Nat. Med.* (2021). doi:10.1038/s41591-021-01316-7
- 410 3. Kawasuji, H. *et al.* Transmissibility of COVID-19 depends on the viral load around onset in
 411 adult and symptomatic patients. *PLoS One* **15**, e0243597 (2020).
- 412 4. Dagan, N. *et al.* BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination
 413 Setting. *N. Engl. J. Med.* **384**, 1412–1423 (2021).
- Teran, R. A. *et al.* Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility
 Residents and Staff Members Chicago, Illinois, December 2020–March 2021. *MMWR*. *Morb. Mortal. Wkly. Rep.* **70**, 632–638 (2021).
- 417 6. Hoffmann, M. *et al.* SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing
 418 antibodies. *Cell* **184**, 2384–2393.e12 (2021).
- Fontanet, A. *et al.* SARS-CoV-2 variants and ending the COVID-19 pandemic. *Lancet*(London, England) **397**, 952–954 (2021).
- 421 8. Wu, K. *et al.* Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. *N. Engl. J. Med.*422 **384**, 1468–1470 (2021).
- 423 9. Rueca, M. *et al.* ESCA pipeline: Easy-to-use SARS-CoV-2 genome Assembler. *bioRxiv*424 2021.05.21.445156 (2021). doi:10.1101/2021.05.21.445156
- 425 10. Shepard, S. S. et al. Viral deep sequencing needs an adaptive approach: IRMA, the iterative

426 refinement meta-assembler. *BMC Genomics* **17**, 708 (2016).

- 11. Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID's innovative
- 428 contribution to global health. *Glob. challenges (Hoboken, NJ)* **1**, 33–46 (2017).
- 429 12. Colavita, F. et al. Virological Characterization of the First 2 COVID-19 Patients Diagnosed in
- Italy: Phylogenetic Analysis, Virus Shedding Profile From Different Body Sites, and Antibody
 Response Kinetics. *Open Forum Infect. Dis.* 7, (2020).
- 432 13. Matusali, G. *et al.* SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand433 New Virus. *Viruses* 13, 655 (2021).
- 434 14. Shilo, S., Rossman, H. & Segal, E. Signals of hope: gauging the impact of a rapid national
 435 vaccination campaign. *Nat. Rev. Immunol.* 21, 198–199 (2021).
- 436 15. Hall, V. J. et al. Do Antibody Positive Healthcare Workers Have Lower SARS-CoV-2
- 437 Infection Rates than Antibody Negative Healthcare Workers? Large Multi-Centre
- 438 Prospective Cohort Study (The SIREN Study), England: June to November 2020. *medRxiv*
- 439 (2021). doi:10.2139/ssrn.3768524
- Keehner, J. *et al.* SARS-CoV-2 Infection after Vaccination in Health Care Workers in
 California. *N. Engl. J. Med.* **384**, 1774–1775 (2021).
- 17. Thompson, M. G. et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and
- 443 mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care
- 444 Personnel, First Responders, and Other Essential and Frontline Workers Eight U.S.
- 445 Locations, December 2020-March. *MMWR. Morb. Mortal. Wkly. Rep.* **70**, 495–500 (2021).
- 18. Haas, E. J. et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-
- 447 2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide
- 448 vaccination campaign in Israel: an observational study using national surveillance data.
- 449 *Lancet* (2021). doi:10.1016/S0140-6736(21)00947-8
- 450 19. Shah, A. et al. Effect of vaccination on transmission of COVID-19: an observational study in

451 healthcare workers and their households. *medRxiv* 2021.03.11.21253275 (2021).

- 452 20. Wölfel, R. *et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature*453 581, 465–469 (2020).
- 454 21. Jaafar, R. et al. Correlation Between 3790 Quantitative Polymerase Chain Reaction-
- 455 Positives Samples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory
- 456 Syndrome Coronavirus 2 Isolates. Clin. Infect. Dis. (2020). doi:10.1093/cid/ciaa1491
- 457 22. Birhane, M. *et al.* COVID-19 Vaccine Breakthrough Infections Reported to CDC United
 458 States, January 1–April 30, 2021. *MMWR. Morb. Mortal. Wkly. Rep.* 70, 792–793 (2021).
- 459 23. Vilches, T. N., Zhang, K., Van Exan, R., Langley, J. M. & Moghadas, S. M. Projecting the

460 impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada. *Vaccine* 39,
461 2360–2365 (2021).

- 462 24. Kustin, T. *et al.* Evidence for increased breakthrough rates of SARS-CoV-2 variants of
 463 concern in BNT162b2-mRNA-vaccinated individuals. *Nat. Med.* (2021). doi:10.1038/s41591464 021-01413-7
- 465 25. Hacisuleyman, E. *et al.* Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *N.*466 *Engl. J. Med.* NEJMoa2105000 (2021). doi:10.1056/NEJMoa2105000
- 467 26. Rydyznski Moderbacher, C. *et al.* Antigen-Specific Adaptive Immunity to SARS-CoV-2 in
 468 Acute COVID-19 and Associations with Age and Disease Severity. *Cell* 183, 996–1012.e19
 469 (2020).
- Williamson, E. J. *et al.* Factors associated with COVID-19-related death using
 OpenSAFELY. *Nature* 584, 430–436 (2020).
- 472 28. Sanyaolu, A. *et al.* Comorbidity and its Impact on Patients with COVID-19. *SN Compr. Clin.* 473 *Med.* 1–8 (2020). doi:10.1007/s42399-020-00363-4

Table 1. Demographic and epidemiological information available for the study cohort. 475

	Total cases	Cases with known date of vaccination (N=79)				
Characteristic	tested positive after vaccination	Group 1 (n=9,	Group 2 (n=16,	Group 3 (n=54,	p-value ^a	
	(N=94)	11.4%)	20.3%)	68.4%)		
Age (median, range)	55.5 (23-92)	53 (24-59)	57.5 (24-82)	49 (23-87)	0.540	
Gender (n, %)						
Male	38 (40.4%)	2 (22.2%)	8 (50.0%)	22 (40.7%)	0.397	
Female	56 (59.6%)	7 (77.8%)	8 (50.0%)	32 (59.3%)		
Category (n, %)						
HCW	82 (87.2%)	9 (100.0%)	13 (81.3%)	50 (92.6%)	0.228	
Age over 80	12 (12.8%)	-	3 (18.8%)	4 (7.4%)		
Symptoms at diagnosis (n, %)						
Yes	45 (47.9%)	8 (88.9%)	8 (50.0%)	23 (42.6%)	0.037	
No	49 (52.1%)	1 (11.1%)	8 (50.0%)	31 (57.4%)		
Clinical course (n, %)						
Pauci/asymptomatic	61 (64.9%)	5 (55.5%)	10 (62.5%)	38 (70.4%)	0.208	
Mild	26 (27.7%)	2 (22.2%)	6 (37.5%)	13 (24.1%)		
Severe	7 (7.4%)	2 (22.2%)	-	3 (5.5%)		
Hospitalization (n, %)						
Yes	10 (10.6%)	2 (22.2%)	1 (6.3%)	4 (7.4%)	0.046	
Admission to ICU	1 (10.0%)	-	-	-		
No	84 (89.4%)	7 (77.8%)	15 (93.7%)	50 (92.6%)		
COVID-19 outcome (n, %) [#]						
Recovered	83 (97.6%)	9 (100.0%)	15 (100.0%)	46 (95.8%)	0.598	
Dead	2 (2.4%)	-	-	2 (4.2%)		

^aBy Kruskal-Wallis tests (for quantitative variables) and Chi-squared test (for categorical variables); 476

p-values <0.05 were considered as statistically significant (in bold). 477

[#] Available at the time of analysis for: total vaccinees, 85/94; Group 1, 9/9; Group 2, 15/16; Group 3, 48/54. 478

479

Table 2. Factors associated with positive viral cultures on NPS collected from vaccinated 481

individuals at the time of SARS-CoV-2 diagnosis. 482

Variable	Positive viral culture n (%)	Univariate analysis OR (95% Cl)	p-value
RT-PCR, Orf1ab gene (N=84)			
Ct value≤25§ (n=55)	43 (78.2%)	100 20 (12 25 915 07)	<0.001
Ct value>25 (n=29)	1 (3.4%)	100.30 (12.35-815.07)	<0.001
Time of the infection diagnosis (N=72)			
10 days after the second dose [§] (n=49)	27 (55.1%)	4 00 (0 07 0 00)	0.000
10 days before the second dose (n=23)	17 (73.9%)	1.02 (0.37-2.80)	0.966
Presence of symptoms at the diagnosis (N=84)			
Yes [§] (n=44)	24 (54.4%)	4 00 (0 54 0 00)	0.077
No (n=40)	20 (50.0%)	1.20 (0.51-2.83)	0.677
Presence of P.1 VOC (N=57)			
Yes [§] (n=14)	10 (71.4 %)	0.97 (0.25-3.69)	0.962
No (n=43)	31 (72.1%)		
Presence of B.1.1.7 VOC (n=57)			
Yes [§] (n=23)	16 (69.6%)	0.82 (0.26-2.65)	0.744
No (n=34)	26 (76.5%)	0.02 (0.20-2.03)	0.744
Presence of nAb in serum (N=44)			
Yes [§] (n=37)	19 (51.3%)	0.19 (0.02.1.61)	0 1 2 4
No (n=7)	6 (85.7%)	0.18 (0.02-1.61)	0.124
nAb titres in serum (N=44)			
≥1:80 [§] (n=25)	10 (40.0%)	0.28 (0.08.1.02)	0.054
<1:80 (n=19)	14 (73.7%)	0.28 (0.08-1.02)	0.054

Abbreviation: OR, Odds ratio; CI, confidence interval; N, total data available for the analysis; n, number of 483 484 data. Boldface indicates factor significantly associated (p<0.05) with positive viral cultures.

§ Reference group (dummy) 485

486

487

Figure 1. Viral loads and viral culture outcomes in NPS collected in individuals tested 489 positive after first dose vaccination. A) Viral loads detected in all symptomatic and 490 491 asymptomatic individuals at the time of diagnosis (left, n=45 and 49, respectively), in a subgroup including only individuals tested positive after 10 days from second dose vaccination (right; n=24 492 and 32, respectively). B) Viral loads detected in NPS collected at different time points from first 493 494 dose vaccination. Group 1 (time lapse 1-15 days), n=7; Group 2 (16-30 days), n=16; Group 3 (>30 495 days), n= 56. Viral RNA levels are expressed as Ct of Orf1ab gene amplification, horizontal dashed 496 line represents the limit of detection of RT-PCR (Ct: 40.0). Median Ct values and IQR are shown. Statistical analysis was performed by Mann–Whitney test, p=0.053 (left) and p=0.098 (right) in (A), 497 and by Kruskal-Wallis test, p=0.135 in (B). Samples yielding positive or negative viral culture are 498 499 indicated in red and black, respectively; empty dots indicate samples for which viral culture was not 500 performed.

Figure 2. Viral loads and viral culture outcomes in NPS collected in individuals tested positive at different time from the first dose vaccination. Viral RNA levels are expressed as Ct of Orf1ab gene amplification, horizontal dashed lines represent the limit of detection of RT-PCR (Ct: 40). Samples yielding positive or negative viral culture are indicated in red and black, respectively; empty dots indicate samples for which viral culture was not performed. Vertical dashed line represents the time of second dose vaccine administration.

Figure 3. Antibody levels in vaccinated individuals tested positive for SARS-CoV-2. A) 507 508 Antibody titers anti-RBD Spike IgG and B) nAb according to the different time-points from first dose vaccination to testing (n=44; Group 1, n=3; Group 2, n=11; Group 3, n= 30). Antibody levels are 509 expressed as BAU/ml in (A) and reciprocal of serum dilution shown on a log2 scale in (B). Dashed 510 line represents the limits of detection of the serological assays (7 BAU/ml in (A) and 1:10 in (B). 511 Median values and IQR are shown, and statistical analysis was performed by Kruskal-Wallis tests, 512 513 p=0.0007 in (A) and p=0.0089 in (B). Mann-Whitney test for single comparisons was also 514 performed, p values are shown in the graph: *p<0.05; **p<0.01. Samples positive or negative for anti-N IgG are indicated in red and black, respectively. Samples yielding positive or negative viral 515

- 516 culture are indicated in red and black, respectively; empty dots indicate samples for which viral
- 517 culture was not performed.

518 **Figure 4. Temporal distribution of PANGO lineages of SARS-CoV-2 genomes.** Sequences

- obtained from unvaccinated individuals (A-B) and from vaccinated subjects (C-D) in Lazio Region
- 520 (Central Italy) between January and March 2021 are shown as absolute frequencies (A and C) and
- 521 percentages (B and D). Others included strains belonging to B.1.177 lineage, B.1.525 lineage,
- 522 B.1.1 lineage, B.1.1.39 lineage, B.1 lineage, and B.1.258.17 lineage.

524 Supplementary Figures

Supplementary Figure 1. Antibody levels in vaccinated individuals tested positive for SARS-525 526 CoV-2 according to the clinical course. Neutralizing antibodies detected in all individuals 527 classified as pauci/asymptomatic (n=31), mild (n=15), and severe (n=4) are shown on the left, those detected only in infections diagnosed after 10 days from second dose vaccination are 528 shown on the right (pauci/asymptomatic, n=19; mild, n=7; severe, n=2). nAb levels are expressed 529 as the reciprocal of serum dilution. Dashed line represents the limits of detection of 1:10. Median 530 531 values and IQR are shown, and statistical analysis was performed by Kruskal-Wallis test, p=0.220 (left) and p=0.556 (right). 532

Supplementary Figure 2. SARS-CoV-2 strains detected in NPS samples collected from post-533 vaccination infections. A) Percentages over a total of 63 sequences obtained are shown. Viral 534 535 lineages detected in all vaccinated individuals (pie chart above) and divided according to the time elapsed from the first dose of vaccine to infection diagnosis (pie charts below) are indicated: 536 Group 1 (time lapse 1-15 days), n=9; Group 2 (16-30 days), n=10; Group 3 (>30 days), n=34; 537 Unknown, vaccination date not available, n=10. B) Absolute frequencies of viral lineages 538 sequenced from the different vaccinated groups according to the time (month 2021) of infection 539 diagnosis. VOI included B.1.525 lineage; Other includes strains belonging to B.1.1 lineage, 540 B.1.1.39 lineage, B.1 lineage, and B.1.258.17 lineage. 541

542 Supplementary Figure 3. Amino acid substitutions found in the Spike protein of SARS-CoV-543 2 sequences obtained from NGS analysis of vaccinated individuals. Mutations are shown 544 according to the different vaccinated groups identified on the basis of the time elapsed from the 545 first dose of vaccine to testing: Group 1 (time lapse 1-15 days), n=8; Group 2 (16-30 days), n=10; 546 Group 3 (>30 days), n=30; VTU: Vaccination time unknown, n=9. Mutations found in the receptor-547 binding domain (RBD) sequence are reported in light-red colour; mutations that cannot be 548 confirmed nor excluded due to low coverage are reported in grey colour.

Supplementary Figure 4. Viral loads and viral culture outcomes in NPS collected in 550 individuals tested positive after first dose vaccination according to the infecting SARS-CoV-551 552 2 variants. Viral RNA levels are expressed as cycle threshold values (Ct) of Orf1ab gene amplification, horizontal dashed line represents the limit of detection of RT-PCR (Ct: 40). Median 553 Ct values and IQR are shown (n=63; B.1.177, n=15; B.1.1.7, n=28; P.1, n=14; other, n=6), and 554 statistical analysis was performed by Kruskal-Wallis test, p=0.109. Samples yielding positive or 555 556 negative viral culture are indicated in red and black, respectively; empty dots indicate samples for 557 which viral culture was not performed.

Supplementary Table 1. Vaccinated individuals with available matching data on antibody 559

560 and RNA viral levels.

ID	Viral load (Ct values)	Viral culture	Viral Strain	anti-S IgG (BAU/mL ≥7.1)	anti-N IgG (Index ≥1,4)	nAb (VNT90≥1:10)	DTV	DSV
1	17.1	Positive	B.1.177	<7.1	0.02	<1:10	8	n.a.
2	19.3	Positive	B.1.177	158.2	0.02	<1:10	14	14
3	21.5	Positive	B.1.177	25.9	0.02	1:10	15	12
4	18.2	Positive	B.1.177	1130.6	0.02	<1:10	16	13
5	26.0	Negative	B.1.177	5549.1	0.56	1:160	22	22
6	16.4	Positive	B.1.525	11360.0	0.16	1:1260	25	21
7	36.8	Negative	n.p.	11360.0	1.08	1:1260	25	21
8	38.0	Negative	n.p.	1615.2	0.11	1:80	26	24
9	33.4	Negative	n.p.	733.2	0.03	1:20	28	24
10	22.0	Positive	B.1.177	5306.6	0.02	1:160	28	n.a.
11	16.5	Positive	P.1	2.284.60	0.56	1:320	28	n.a.
12	31.0	Negative	n.p.	2678.0	6.47	1:1260	29	n.a.
13	31.3	n.p.	n.p.	1174.1	4.35	1:160	30	n.a.
14	15.0	Negative	P.1	9889.7	0.05	1:320	30	27
15	15.6	Positive	B.1.1.7	17.1	0.02	<1:10	31	31
16	26.6	Negative	B.1.177	4397.2	0.81	1:1260	31	n.a.
17	11.7	Positive	B.1.177	3311.7	0.11	1:80	33	n.a.
18	26.3	Positive	B.1.177	208.8	0.01	1:160	36	n.a.
19	20.1	Positive	B.1.1.39	1632.8	0.03	1:160	36	n.a.
20	39.0	Negative	B.1.1.7	<7.1	0.02	<1:10	37	37
21	17.1	Negative	P.1	799.1	0.19	1:80	38	n.a.
22	38.0	Negative	n.p.	313.7	0.17	1:1260	47	n.a.
23	32.6	n.p.	n.p.	2453.0	0.07	1:80	47	n.a.
24	15.8	Positive	n.p.	950.8	0.01	1:80	48	n.a.
25	21.9	Positive	n.p.	467.3	0.05	1:40	49	45
26	15.8	Positive	P.1	861.7	0.07	1:320	49	46
27	32.0	Negative	n.p.	568.2	0.04	1:40	49	47
28	18.3	Positive	B.1.1.7	2179.8	0.04	1:160	50	n.a.
29	27.2	Negative	n.p.	825.7	0.17	1:160	55	53
30	21.3	Positive	B.1.1.7	575.0	0.08	1:40	59	n.a.
31	15.3	Positive	B.1.177	200.8	0.03	1:40	64	57
32	39.0	Negative	n.p.	529.8	0.01	1:20	66	n.a.
33	39.0	Negative	n.p.	1379.6	0.06	1:160	67	n.a.
34	15.6	Positive	B.1.1.7	70.2	0.02	1:10	68	n.a.
35	17.5	Positive	B.1.1.7	599.1	0.05	1:160	68	64
36	39.0	Negative	n.p.	1742.9	2.55	1:160	69	n.a.
						(contir	nued nex	t page)

37	21.5	n.p.	B.1.1.7	475.0	0.04	1:20	69	n.a.
38	17.3	Positive	B.1.1.7	208.8	0.01	1:160	70	67
39	22.0	n.p.	P.1	1903.1	0.02	1:160	70	n.a.
40	13.6	Positive	P.1	574.7	0.03	1:40	72	70
41	38.0	Negative	n.p.	3569.7	0.49	1:1260	72	n.a.
42	36.6	Negative	n.p.	597.9	0.1	1:20	74	73
43	32.0	n.p.	n.p.	481.2	0.54	1:40	78	n.a.
44	21.6	Positive	B.1.1.7	506.8	0.01	1:20	83	n.a.
45	20.0	Negative	P.1	676.6	0.02	1:80	n.a.	n.a.
46	18.9	n.p.	B.1.1.7	69.6	0.03	<1:10	n.a.	n.a.
47	16.3	Positive	P.1	732.6	0.02	1:40	n.a.	n.a.
48	14.2	Positive	B.1.1.7	382.6	0.02	<1:10	n.a.	n.a.
49	33.1	Negative	n.p.	609.5	0.3	1:80	n.a.	n.a.
50	12.1	Positive	B.1.1.7	36.3	0.02	<1:10	n.a.	n.a.

Abbreviation: DTV, days from first dose vaccination to testing; DSV, days from first dose vaccination to 561

562 symptoms onset (for symptomatic individuals only); n.p., not performed; n.a., not available, as vaccination

563 date unknown, or absence of symptoms at diagnosis.







Figure 3.



Figure 4.



Figure S1.



Figure S2.



B)		January	February	March
	B.1.177	6	1	
	B.1.1.7			1
Group 1	P.1			
	VOI			
	Other	1		
	B.1.177		4	
	B.1.1.7			
Group 2	P.1		1	1
	VOI		1	
	Other		1	2
	B.1.177		2	1
	B.1.1.7		1	18
Group 3	P.1			11
	VOI			
	Other		1	
	B.1.177	1		
Vaccination	B.1.1.7			7
date	P.1			2
unknown	VOI			
	Other			

Figure S3.





